Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biochrom Introduces EZ Nin Reagent for Improved Amino Acid Analysis

Published: Tuesday, February 25, 2014
Last Updated: Monday, February 24, 2014
Bookmark and Share
Ready to use ninhydrin formulation for ion exchange chromatography systems.

Biochrom Ltd has announced the commercial launch of its EZ Nin Reagent™, a ready-to-use ninhydrin formulation for use in ion exchange chromatography systems with post-column derivatisation for improved amino acid analysis.

The newly launched and patent protected EZ Nin Reagent has been developed to save laboratory time and waste; it requires no mixing or nitrogen and does not degrade with time or exposure to oxygen, providing reliable analysis over time without loss of sensitivity.

Challenges encountered with standard ninhydrin include the long preparation process, instability of the reagent, degradation and waste, and batch-to-batch variability.

Each batch of EZ Nin Reagent is identically prepared, enabling the reagent to be topped up on the instrument, eliminating waste or the risk of running out during a series of analyses. EZ Nin Reagent is methanol and hydrindantin free.

Tristana von Will, Product Marketing Manager at Biochrom, commented: “Biochrom’s formulation combines ease of use with unprecedented chemical stability, providing laboratories with the confidence they require when evaluating concentrations of amino acids for diagnosis and monitoring of inborn errors of metabolism (IEMs).”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biochrom, Gilson Sign ELISA Distribution Agreement
Companies to co-market and distribute products for automation of ELISAs and other absorbance assays in Europe.
Tuesday, June 10, 2014
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!